CMA1 and cardiovascular disorder: Considering that cardiovascular diseases are still the leading cause of death in the U.S. and in developed countries in general, and that the control of hypertension greatly reduces the risk of stroke and heart failure [3], treatment with chymase inhibitors during the acute phase of myocardial infarction represents a potentially useful strategy in reducing cardiac dysfunction, involving targets other than ACE suppression [4].